US5171569A
(en)
*
|
1985-03-15 |
1992-12-15 |
National Research Development Corporation |
Factor IX preparations uncontaminated by plasma components or pox virus
|
ZA862768B
(en)
*
|
1985-04-17 |
1986-12-30 |
Zymogenetics Inc |
Expression of factor vii and ix activities in mammalian cells
|
DE3684546D1
(de)
*
|
1985-04-22 |
1992-04-30 |
Genetics Inst |
Herstellung mit hoher leistung des aktivfaktors ix.
|
US5516650A
(en)
*
|
1985-06-27 |
1996-05-14 |
Zymogenetics, Inc. |
Production of activated protein C
|
US4968626A
(en)
*
|
1985-08-15 |
1990-11-06 |
Board Of Reagents Of The University Of Washington |
DNA sequence coding for protein C
|
US4959318A
(en)
*
|
1985-06-27 |
1990-09-25 |
Zymogenetics, Inc. |
Expression of protein C
|
USRE38981E1
(en)
*
|
1985-08-15 |
2006-02-14 |
Board Of Regents Of The University Of Washington |
DNA sequence coding for protein C
|
CA1281647C
(en)
*
|
1985-11-26 |
1991-03-19 |
Novo Nordisk A/S |
Compositions and methods for the treatment of bleeding disorders
|
IL82648A0
(en)
*
|
1986-05-27 |
1987-11-30 |
Lilly Co Eli |
Human protein s,a plasma protein regulator of hemostasis
|
FR2599752B1
(fr)
*
|
1986-06-10 |
1989-11-03 |
Transgene Sa |
Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
|
FR2600334B1
(fr)
*
|
1986-06-23 |
1989-05-12 |
Transgene Sa |
Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
|
US5258288A
(en)
*
|
1986-07-25 |
1993-11-02 |
Genzyme Corporation |
Vector containing DNA encoding mature human protein S
|
DK323587D0
(da)
*
|
1987-06-25 |
1987-06-25 |
Novo Industri As |
Protein
|
EP0289586A4
(en)
*
|
1986-11-17 |
1990-04-10 |
New England Medical Ct |
INCREASING GAMMA CARBOXYLATION OF RECOMBINANT, VITAMIN K-DEPENDENT PROTEINS.
|
JPH03501921A
(ja)
*
|
1987-05-18 |
1991-05-09 |
インテグレイテッド・ジェネティクス・インク |
改良タンパク質分子、並びにその製造及び活性化方法
|
JP2799316B2
(ja)
*
|
1987-06-12 |
1998-09-17 |
ヘキスト・マリオン・ルセル株式会社 |
雑種ヒトプロテインcおよびその遺伝子工学的製法
|
US5648254A
(en)
*
|
1988-01-15 |
1997-07-15 |
Zymogenetics, Inc. |
Co-expression in eukaryotic cells
|
US5580560A
(en)
*
|
1989-11-13 |
1996-12-03 |
Novo Nordisk A/S |
Modified factor VII/VIIa
|
US5225537A
(en)
*
|
1989-12-29 |
1993-07-06 |
Zymogenetics, Inc. |
Methods for producing hybrid phospholipid-binding proteins
|
US5358932A
(en)
*
|
1989-12-29 |
1994-10-25 |
Zymogenetics, Inc. |
Hybrid protein C
|
DE69131292T2
(de)
*
|
1990-01-29 |
1999-09-30 |
Zymogenetics, Inc. |
Antikoagulierende proteine
|
DE4007902A1
(de)
*
|
1990-03-13 |
1991-09-19 |
Behringwerke Ag |
Synthetische peptide, die sequenzen aus faktor viia enthalten und deren verwendung
|
ATE158816T1
(de)
*
|
1990-11-26 |
1997-10-15 |
Genetics Inst |
Expression von pace in wirtszellen und verfahren zu dessen verwendung
|
US5788965A
(en)
*
|
1991-02-28 |
1998-08-04 |
Novo Nordisk A/S |
Modified factor VII
|
US5833982A
(en)
|
1991-02-28 |
1998-11-10 |
Zymogenetics, Inc. |
Modified factor VII
|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
US20040087498A1
(en)
*
|
1991-02-28 |
2004-05-06 |
Novo Nordisk Health Care Ag |
Modified factor VII
|
US5861374A
(en)
*
|
1991-02-28 |
1999-01-19 |
Novo Nordisk A/S |
Modified Factor VII
|
US5817788A
(en)
*
|
1991-02-28 |
1998-10-06 |
Zymogenetics, Inc. |
Modified factor VII
|
US5876985A
(en)
*
|
1991-04-25 |
1999-03-02 |
Board Of Regents, The University Of Texas System |
Methods and compositions for the preparation of recombinant Trichomonas vaginalis proteins and peptides
|
US6039944A
(en)
*
|
1992-02-28 |
2000-03-21 |
Zymogenetics, Inc. |
Modified Factor VII
|
US5965350A
(en)
*
|
1994-04-08 |
1999-10-12 |
Syntex (U.S.A.) Inc. |
Cloning and expression of human GMP synthetase, its use in screening for inhibitors of human GMP synthetase and inhibitors of human GMP synthetase
|
US5843752A
(en)
*
|
1995-05-12 |
1998-12-01 |
Schering Corporation |
Soluble active hepatitis C virus protease
|
CN1127568C
(zh)
|
1996-10-16 |
2003-11-12 |
津莫吉尼蒂克斯公司 |
成纤维细胞生长因子同系物
|
JP2001510168A
(ja)
|
1997-07-18 |
2001-07-31 |
ノボ ノルディスク アクティーゼルスカブ |
FVIIa媒介性細胞内シグナル伝達経路に関連する反対条件の処理のためのFVIIa又はFVIIaiの使用
|
DE69838483T2
(de)
|
1997-10-14 |
2008-07-03 |
Darwin Molecular Corp. |
Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
|
US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7247708B2
(en)
*
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
EP0927764B1
(de)
*
|
1997-12-03 |
2004-05-26 |
Boehringer Mannheim Gmbh |
Chimäre Serinproteasen
|
US6159722A
(en)
|
1997-12-03 |
2000-12-12 |
Boehringer Mannheim Gmbh |
Chimeric serine proteases
|
AT408613B
(de)
*
|
1998-06-17 |
2002-01-25 |
Immuno Ag |
Pharmazeutisches faktor vii-präparat
|
CN1344320A
(zh)
|
1998-09-23 |
2002-04-10 |
津莫吉尼蒂克斯公司 |
细胞因子受体zalphall
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
CA2352532C
(en)
|
1998-11-27 |
2014-10-14 |
Darwin Discovery Ltd. |
Compositions and methods for increasing bone mineralization
|
EP1137773B1
(en)
|
1998-12-07 |
2008-08-13 |
ZymoGenetics, Inc. |
Growth factor homolog zvegf3
|
US7063850B1
(en)
*
|
1998-12-22 |
2006-06-20 |
University Of Tennessee Research Foundation |
Protective antigen of group A Streptococci
|
EP1141274B2
(en)
|
1999-01-07 |
2014-11-12 |
ZymoGenetics, Inc. |
Soluble receptor br43x2 and methods of using them for therapy
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
MXPA01009074A
(es)
|
1999-03-09 |
2002-03-27 |
Zymogenetics Inc |
Nuevo ligando zalfa11 de citocina.
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
JP4732590B2
(ja)
|
1999-03-15 |
2011-07-27 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1及び近縁ペプチドのイオン交換クロマトグラフィー分離
|
DE10023923A1
(de)
*
|
1999-06-10 |
2000-12-14 |
Aventis Behring Gmbh |
Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
|
US6924359B1
(en)
*
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US20040235715A1
(en)
*
|
1999-11-12 |
2004-11-25 |
Bayer Corporation |
Method of producing glycosylated bikunin
|
DE60043944D1
(de)
|
1999-12-23 |
2010-04-15 |
Zymogenetics Inc |
Zytokin zcyt018
|
DE60138364D1
(de)
*
|
2000-02-11 |
2009-05-28 |
Bayer Healthcare Llc |
Gerinnungsfaktor vii oder viia konjugate
|
EP1276756A4
(en)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US6905683B2
(en)
|
2000-05-03 |
2005-06-14 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII variants
|
EP2258725A3
(en)
|
2000-06-26 |
2014-09-17 |
ZymoGenetics, L.L.C. |
Cytokine receptor zcytor17
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
BR0112119A
(pt)
|
2000-06-30 |
2003-05-06 |
Zymogenetics Inc |
Polipeptìdeo isolado, molécula de ácido nucléico isolado, vetor, célula hospedeira recombinante, método de produzir a proteìna zcyto21, anticorpo ou fragmento de anticorpo, método de detectar a presença da expressão do gene zcyto21 em uma amostra biológica
|
KR100882482B1
(ko)
|
2000-09-13 |
2009-02-06 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
사람 응고 인자 vii 변이체
|
JP4361728B2
(ja)
|
2000-09-13 |
2009-11-11 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
ヒト凝固因子vii変異型
|
FR2814170B1
(fr)
*
|
2000-09-18 |
2005-05-27 |
Rhodia Chimie Sa |
Nouveau latex a proprietes de surface modifiees par l' ajout d'un copolymere hydrosoluble a caractere amphiphile
|
US20040185534A1
(en)
*
|
2000-10-02 |
2004-09-23 |
Knudsen Ida Molgaard |
Industrial-scale serum-free production of recombinant proteins in mammalian cells
|
HUP0301245A3
(en)
*
|
2000-10-02 |
2005-12-28 |
Novo Nordisk Healthcare Ag |
Tmethod for the production of vitamin k-dependent proteins
|
US7615537B2
(en)
*
|
2000-10-25 |
2009-11-10 |
Genzyme Corporation |
Methods for treating blood coagulation disorders
|
AU2002218029A1
(en)
|
2000-11-09 |
2002-05-21 |
The Scripps Research Institute |
Modified factor viia
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
CA2441580A1
(en)
|
2001-03-22 |
2002-10-03 |
Novo Nordisk Health Care Ag |
Coagulation factor vii derivatives
|
US20040219543A1
(en)
*
|
2001-04-02 |
2004-11-04 |
Ralph Wirtz |
Method for specifically detecting, isolating and characterizing cells from body samples by transfecting nucleic acid constructs
|
WO2002090600A2
(en)
|
2001-05-08 |
2002-11-14 |
Darwin Molecular Corporation |
A method for regulating immune function in primates using the foxp3 protein
|
AU2002333211B2
(en)
|
2001-09-27 |
2008-05-08 |
Novo Nordisk Health Care Ag |
Human coagulation factor VII polypeptides
|
US7052868B2
(en)
|
2001-09-27 |
2006-05-30 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
EP2298354B1
(en)
|
2001-10-10 |
2014-03-19 |
ratiopharm GmbH |
Remodelling and glycoconjugation of interferon-beta
|
SG159381A1
(en)
|
2001-10-10 |
2010-03-30 |
Novo Nordisk As |
Remodeling and glycoconjugation of peptides
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
MXPA04003852A
(es)
*
|
2001-10-26 |
2005-02-17 |
Univ Tennessee Res Foundation |
Composiciones de vacuna estreptococica multivalente, y metodos para sus uso.
|
US6960657B2
(en)
|
2001-11-02 |
2005-11-01 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
ATE444363T1
(de)
|
2001-11-05 |
2009-10-15 |
Zymogenetics Inc |
Il-21-antagonisten
|
JP2005511601A
(ja)
*
|
2001-11-09 |
2005-04-28 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第vii因子ポリペプチドおよび組織プラスミノゲン阻害剤を含む薬学的組成物
|
US20030119743A1
(en)
*
|
2001-11-09 |
2003-06-26 |
Rasmus Rojkjaer |
Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
|
WO2003039589A1
(en)
*
|
2001-11-09 |
2003-05-15 |
Novo Nordisk Health Care Ag |
Pharmaceutical composition comprising factor vii polypeptides and alpha2 -antiplasmin polypeptides
|
US7078479B2
(en)
|
2001-11-09 |
2006-07-18 |
Novo Nordisk Healthcare A/G |
Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
ATE428439T1
(de)
*
|
2001-12-21 |
2009-05-15 |
Novo Nordisk Healthcare Ag |
Flüssige zusammensetzung aus faktor vii polypeptiden
|
JP2006506317A
(ja)
|
2002-01-11 |
2006-02-23 |
バイオマリン ファーマシューティカル インコーポレイテッド |
治療用リソソーム酵素の送達のための酵素送達系としてのp97の使用
|
EP2230299B1
(en)
|
2002-01-18 |
2011-12-07 |
ZymoGenetics, Inc. |
Novel cytokine ZCYTOR17 ligand
|
SI1576112T1
(sl)
|
2002-01-18 |
2012-10-30 |
Zymogenetics Inc |
Multimerni citokinski receptor zcitor17
|
EP2295455A1
(en)
|
2002-04-19 |
2011-03-16 |
ZymoGenetics, L.L.C. |
Cytokine receptor
|
AU2003221469A1
(en)
*
|
2002-04-30 |
2003-11-17 |
Bayer Healthcare Llc |
FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
PL207018B1
(pl)
|
2002-06-21 |
2010-10-29 |
Novo Nordisk Helth Care Ag |
Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
|
WO2004000366A1
(en)
|
2002-06-21 |
2003-12-31 |
Novo Nordisk Health Care Ag |
Pegylated factor vii glycoforms
|
US6933136B2
(en)
*
|
2002-09-20 |
2005-08-23 |
Novo Nordisk A/S |
Method for making recombinant proteins
|
WO2004029090A1
(en)
|
2002-09-25 |
2004-04-08 |
Novo Nordisk Health Care Ag |
Human coagulation factor vii polypeptides
|
US6911323B2
(en)
|
2002-09-25 |
2005-06-28 |
Novo Nordisk Healthcare A/G |
Human coagulation factor VII polypeptides
|
KR101204712B1
(ko)
|
2003-03-18 |
2012-11-27 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
Gla-잔기 함유 세린 프로테아제의 제조 방법
|
RU2005132164A
(ru)
*
|
2003-03-18 |
2006-06-10 |
Ново Нордиск Хелт Кэр Аг (Ch) |
Жидкие, водные фармацевтические композиции полипептидов фактора vii
|
AU2004221761B2
(en)
*
|
2003-03-20 |
2010-01-07 |
Bayer Healthcare Llc |
FVII or FVIIa variants
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
EP1615945B1
(en)
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
AU2004238263A1
(en)
*
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
TWI353991B
(en)
*
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP1624891B2
(en)
*
|
2003-05-06 |
2013-04-10 |
Biogen Idec Hemophilia Inc. |
Clotting factor-fc chimeric proteins to treat hemophilia
|
MXPA05012476A
(es)
*
|
2003-05-23 |
2006-02-22 |
Novo Nordisk Healthcare Ag |
Estabilizacion de proteina en solucion.
|
NZ573412A
(en)
*
|
2003-06-19 |
2010-09-30 |
Maxygen Holdings Ltd |
Factor VII or VIIa Gla domain variants
|
ES2382157T3
(es)
*
|
2003-06-25 |
2012-06-05 |
Novo Nordisk Health Care Ag |
Composición líquida de polipépttidos del factor VII
|
ES2335994T3
(es)
*
|
2003-07-01 |
2010-04-07 |
Novo Nordisk Health Care Ag |
Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
WO2005044849A2
(en)
*
|
2003-08-05 |
2005-05-19 |
Eli Lilly And Company |
Lp mammalian proteins; related reagents
|
JP4808157B2
(ja)
|
2003-08-07 |
2011-11-02 |
ザイモジェネティクス リミテッド ライアビリティ カンパニー |
Il−28およびil−29の均一な調製物
|
KR101293503B1
(ko)
|
2003-08-14 |
2013-08-07 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
인자 vii 폴리펩티드의 액상 수성 약학적 조성물
|
JP4824559B2
(ja)
|
2003-09-09 |
2011-11-30 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
凝固因子viiポリペプチド
|
GB0324044D0
(en)
*
|
2003-10-14 |
2003-11-19 |
Astrazeneca Ab |
Protein
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
EP3594222B1
(en)
|
2003-12-01 |
2022-08-03 |
Novo Nordisk Health Care AG |
Virus filtration of liquid factor vii compositions
|
CA2549593C
(en)
|
2003-12-19 |
2014-02-11 |
Novo Nordisk Health Care Ag |
Stabilised compositions of factor vii polypeptides
|
ES2642214T3
(es)
|
2004-01-21 |
2017-11-15 |
Novo Nordisk Health Care Ag |
Conjugación de péptidos mediante transglutaminasa
|
EP1732946B1
(en)
|
2004-03-08 |
2011-07-27 |
ZymoGenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
AU2005266892B2
(en)
|
2004-07-29 |
2011-03-03 |
Bristol-Myers Squibb Company |
Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
|
BRPI0514396A2
(pt)
*
|
2004-08-17 |
2009-05-12 |
Csl Behring Gmbh |
polipeptìdeos dependentes de vitamina k modificada
|
HUE026826T2
(en)
|
2004-10-29 |
2016-07-28 |
Ratiopharm Gmbh |
Modeling and glycopegylation of fibroblast growth factor (FGF)
|
KR101364001B1
(ko)
|
2004-12-23 |
2014-02-17 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
관심있는 비타민 k-의존성 단백질을 포함한 조성물 중의단백질 오염물질의 양의 감소
|
ES2449195T3
(es)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Factor estimulante de colonias de granulocitos glicopegilado
|
WO2006121569A2
(en)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
KR20130140221A
(ko)
|
2005-04-13 |
2013-12-23 |
아스트라제네카 아베 |
감마 카르복실화를 필요로 하는 단백질 생산용 벡터를 포함하는 숙주 세포
|
EP1728798A1
(en)
|
2005-06-01 |
2006-12-06 |
ZLB Behring GmbH |
Coagulation factor X polypeptides with modified activation properties
|
EP1893632B1
(en)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
|
ZA200800251B
(en)
*
|
2005-06-24 |
2009-04-29 |
Drugrecure Aps |
Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
|
CA2618763A1
(en)
|
2005-08-09 |
2007-02-15 |
Zymogenetics, Inc. |
Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
|
AR059945A1
(es)
*
|
2005-08-09 |
2008-05-14 |
Zymogenetics Inc |
Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
ES2515915T3
(es)
|
2005-09-01 |
2014-10-30 |
Novo Nordisk Health Care Ag |
Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica
|
WO2007031559A2
(en)
|
2005-09-14 |
2007-03-22 |
Novo Nordisk Health Care Ag |
Human coagulation factor vii polypeptides
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
EP1820508A1
(en)
|
2006-02-21 |
2007-08-22 |
CSL Behring GmbH |
Coagulation factor X polypeptides with modified activation properties
|
ES2399138T3
(es)
*
|
2006-03-16 |
2013-03-26 |
Stellaris Pharmaceuticals Aps |
Tratamiento local con factor VII
|
GB0606190D0
(en)
|
2006-03-28 |
2006-05-10 |
Isis Innovation |
Construct
|
PL2007885T3
(pl)
|
2006-04-11 |
2010-12-31 |
Csl Behring Gmbh |
Sposób zwiększania odzysku peptydów terapeutycznych in vivo
|
NZ572373A
(en)
*
|
2006-05-15 |
2012-02-24 |
Ares Trading Sa |
Methods for treating rheumatoid arthritis using a taci-ig fusion molecule
|
FR2901707B1
(fr)
|
2006-05-31 |
2017-09-29 |
Lab Francais Du Fractionnement |
Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
|
KR101641899B1
(ko)
|
2006-06-14 |
2016-08-01 |
체에스엘 베링 게엠베하 |
혈액 응고 인자를 포함하는 단백질분해적으로 절단가능한 융합 단백질
|
US7939632B2
(en)
*
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
EP1867660A1
(en)
|
2006-06-14 |
2007-12-19 |
CSL Behring GmbH |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
ES2516694T3
(es)
|
2006-07-21 |
2014-10-31 |
Ratiopharm Gmbh |
Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
|
JP5570809B2
(ja)
|
2006-09-01 |
2014-08-13 |
ノボ ノルディスク ヘルス ケア アーゲー |
修飾タンパク質
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
EP2094301A4
(en)
*
|
2006-11-30 |
2012-02-01 |
Taplmmune Inc |
TREATMENT OF POXVIRIDAE COMPRISING TAP-1 AND / OR TAP-2 AS MOLECULAR ADJUVANT
|
PT2101821E
(pt)
|
2006-12-15 |
2014-10-03 |
Baxter Int |
Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
|
US8754194B2
(en)
*
|
2006-12-22 |
2014-06-17 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
FR2910786B1
(fr)
|
2006-12-29 |
2017-08-11 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) |
"procede d'extraction d'une proteine presente dans du lait"
|
US20100143326A1
(en)
*
|
2007-01-03 |
2010-06-10 |
Novo Nordisk Healthcare A/G |
SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
|
PL2144923T3
(pl)
|
2007-04-03 |
2013-12-31 |
Biogenerix Ag |
Sposoby leczenia z użyciem glikopegilowanego G-CSF
|
NZ579985A
(en)
*
|
2007-04-13 |
2012-02-24 |
Catalyst Biosciences Inc |
Modified factor vii polypetides and uses thereof
|
US9493499B2
(en)
|
2007-06-12 |
2016-11-15 |
Novo Nordisk A/S |
Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
|
US8206967B2
(en)
*
|
2007-07-06 |
2012-06-26 |
Medimmune Limited |
Method for production of recombinant human thrombin
|
EP2574676B1
(en)
|
2007-12-27 |
2017-08-30 |
Baxalta GmbH |
Cell culture processes
|
WO2009108806A1
(en)
|
2008-02-27 |
2009-09-03 |
Novo Nordisk A/S |
Conjugated factor viii molecules
|
JP5425180B2
(ja)
|
2008-03-27 |
2014-02-26 |
ザイモジェネティクス, インコーポレイテッド |
PDGFRβおよびVEGF−Aを阻害するための組成物および方法
|
TWI538916B
(zh)
|
2008-04-11 |
2016-06-21 |
介控生化科技公司 |
經修飾的因子vii多肽和其用途
|
EP2623112B1
(en)
|
2008-06-27 |
2015-03-04 |
Zymogenetics, Inc. |
Soluble hybrid Fc gamma receptors and related methods
|
EP2977461A1
(en)
*
|
2008-11-12 |
2016-01-27 |
Baxalta Incorporated |
Method of producing serum-free insulin-free factor vii
|
JP5936112B2
(ja)
|
2009-02-11 |
2016-06-15 |
アルブミディクス アクティーゼルスカブ |
アルブミン変異体及び複合体
|
FR2942231B1
(fr)
|
2009-02-19 |
2015-03-20 |
Lfb Biotechnologies |
Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations
|
WO2010149172A2
(en)
|
2009-06-24 |
2010-12-29 |
Rigshospitalet |
SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
|
FR2947181B1
(fr)
|
2009-06-26 |
2012-05-04 |
Lfb Biotechnologies |
Composition de facteur vii
|
US20120148557A1
(en)
|
2009-08-20 |
2012-06-14 |
Ulrich Kronthaler |
Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
|
US20120263701A1
(en)
|
2009-08-24 |
2012-10-18 |
Volker Schellenberger |
Coagulation factor vii compositions and methods of making and using same
|
CA2776241A1
(en)
|
2009-10-30 |
2011-05-05 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
WO2011053738A1
(en)
|
2009-10-30 |
2011-05-05 |
Inspiration Biopharmaceuticals, Inc. |
Method of producing recombinant vitamin k dependent proteins
|
JP5984676B2
(ja)
|
2009-12-18 |
2016-09-06 |
シーエスエル、リミテッド |
ポリペプチドを精製する方法
|
WO2011124718A1
(en)
|
2010-04-09 |
2011-10-13 |
Novozymes A/S |
Albumin derivatives and variants
|
CA2802017A1
(en)
|
2010-06-09 |
2011-12-15 |
Zymogenetics, Inc. |
Dimeric vstm3 fusion proteins and related compositions and methods
|
WO2012057527A2
(en)
*
|
2010-10-26 |
2012-05-03 |
Hanmi Holdings Co., Ltd. |
Method for mass production of factor vii/viia
|
TWI557135B
(zh)
|
2010-11-03 |
2016-11-11 |
介控生化科技公司 |
經修飾之第九因子多胜肽及其用途
|
US9150846B2
(en)
|
2011-07-05 |
2015-10-06 |
Bioasis Technologies, Inc. |
P97-antibody conjugates and methods of use
|
PT2739649T
(pt)
|
2011-08-05 |
2018-01-03 |
Bioasis Technologies Inc |
Fragmentos de p97 com atividade de transferência
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
SG10201606285YA
(en)
|
2012-02-01 |
2016-09-29 |
Synthetic Genomics Inc |
Materials and methods for the synthesis of error-minimized nucleic acid molecules
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
LT2814840T
(lt)
|
2012-02-15 |
2020-02-25 |
Bioverativ Therapeutics Inc. |
Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
|
EP3330283A3
(en)
|
2012-03-16 |
2018-07-11 |
Albumedix A/S |
Albumin variants
|
EP2687595B1
(en)
|
2012-07-19 |
2018-05-30 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Method for purifying transgenic factor VII
|
AU2013296557B2
(en)
|
2012-07-31 |
2019-04-18 |
Bioasis Technologies Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
CN104717973A
(zh)
|
2012-10-10 |
2015-06-17 |
诺和诺德保健Ag(股份有限公司) |
因子vii多肽的液体药物组合物
|
WO2014060401A1
(en)
|
2012-10-15 |
2014-04-24 |
Novo Nordisk Health Care Ag |
Coagulation factor vii polypeptides
|
EP2906247A1
(en)
|
2012-10-15 |
2015-08-19 |
Novo Nordisk Health Care AG |
Factor vii conjugates
|
EP2917233A1
(en)
|
2012-11-08 |
2015-09-16 |
Novozymes Biopharma DK A/S |
Albumin variants
|
CN110478481A
(zh)
|
2013-03-13 |
2019-11-22 |
比奥阿赛斯技术有限公司 |
p97片段及其应用
|
AU2014236208B2
(en)
|
2013-03-14 |
2018-07-19 |
Genvivo, Inc. |
Thymidine kinase diagnostic assay for gene therapy applications
|
AU2013204728B2
(en)
|
2013-03-15 |
2016-09-15 |
Baxalta GmbH |
Methods for treating bleeding disorders using a platelet subpopulation
|
UY35463A
(es)
|
2013-03-15 |
2014-10-31 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix.
|
FR3006591B1
(fr)
|
2013-06-11 |
2016-05-06 |
Lab Francais Du Fractionnement |
Composition de facteur vii presentant un point isoelectrique substantiellement homogene
|
EP3033097B1
(en)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Factor viii-xten fusions and uses thereof
|
JP6603227B2
(ja)
|
2014-02-03 |
2019-11-06 |
バイオアシス テクノロジーズ インコーポレイテッド |
P97融合タンパク質
|
WO2015126729A1
(en)
|
2014-02-19 |
2015-08-27 |
Bioasis Technologies, Inc. |
P97-ids fusion proteins
|
CA2943890A1
(en)
|
2014-05-01 |
2015-11-05 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
BR102015012334A2
(pt)
|
2015-05-27 |
2016-11-29 |
Fundação Hemoct De Ribeirão Preto Fundherp |
processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
|
EP3307237A1
(en)
|
2015-06-12 |
2018-04-18 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Injectable composition of factor vii and fillers
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
WO2017029407A1
(en)
|
2015-08-20 |
2017-02-23 |
Albumedix A/S |
Albumin variants and conjugates
|
WO2017044424A1
(en)
|
2015-09-08 |
2017-03-16 |
Theripion, Inc. |
Apoa-1 fusion polypeptides and related compositions and methods
|
WO2018136163A2
(en)
|
2016-12-09 |
2018-07-26 |
Theripion, Inc. |
Tandem apoa-1 fusion polypeptides
|
WO2019016402A1
(en)
|
2017-07-20 |
2019-01-24 |
Aptevo Research And Development Llc |
BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO
|
WO2019094521A1
(en)
|
2017-11-07 |
2019-05-16 |
Rani Therapeutics, Llc |
Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
|
BR112020012364A2
(pt)
|
2017-12-20 |
2020-11-24 |
Harbour Biomed (Shanghai) Co., Ltd |
anticorpos de ligação a ctla-4 e usos dos mesmos
|
US10150801B1
(en)
|
2017-12-27 |
2018-12-11 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
WO2019132765A1
(en)
|
2017-12-27 |
2019-07-04 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
AU2019270184A1
(en)
|
2018-05-18 |
2020-11-26 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia A
|
FR3082427B1
(fr)
|
2018-06-14 |
2020-09-25 |
Lab Francais Du Fractionnement |
Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
|
CA3133357A1
(en)
*
|
2019-03-27 |
2020-10-01 |
Sigilon Therapeutics, Inc. |
Compositions, devices and methods for factor vii therapy
|
EP3833381B1
(en)
|
2019-08-15 |
2022-08-03 |
Catalyst Biosciences, Inc. |
Modified factor vii polypeptides for subcutaneous administration
|
US10675332B1
(en)
|
2019-08-26 |
2020-06-09 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
WO2021040610A1
(en)
|
2019-08-26 |
2021-03-04 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
EP4168034A1
(en)
|
2020-06-22 |
2023-04-26 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and combinations for use in the treatment of cancer
|
EP4203989A2
(en)
|
2020-09-03 |
2023-07-05 |
Rampart Bioscience, Inc. |
Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
|
WO2022178090A2
(en)
|
2021-02-19 |
2022-08-25 |
Theripion, Inc. |
Dnase fusion polypeptides and related compositions and methods
|
WO2024042148A1
(en)
|
2022-08-26 |
2024-02-29 |
Stellaris Pharmaceuticals Aps |
Haemorrhage inhibiting compositions and methods involving the same
|
WO2024148328A2
(en)
|
2023-01-06 |
2024-07-11 |
Aptevo Research And Development Llc |
Bispecific pd-l1 and cd40 binding molecules and uses thereof
|